AVINGER,INC. (NASDAQ:AVGR) Files An 8-K Changes in Registrant’s Certifying Accountant

AVINGER,INC. (NASDAQ:AVGR) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01. Changes in Registrant’s Certifying Accountant.

Story continues below

(a) On October11, 2017, Avinger,Inc. (the “Company”) dismissed Ernst& Young LLP (“E&Y”) as its independent registered public accounting firm. The audit committee of the Board of Directors (the “Board”) recommended such dismissal and the Board approved such dismissal, effective as of October11, 2017.

The reports of E&Y on the Company’s financial statements for the past two fiscal years did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that E&Y’s audit report on the December31, 2016 financial statements contained an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern.

In connection with the audits of the Company’s financial statements for each of the two fiscal years ended December31, 2016, and in the subsequent interim period through October11, 2017, there were (i)no disagreements within the meaning of Item 304(a)(1)(iv)of Regulation S-K between the Company and E&Y on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of E&Y would have caused E&Y to make reference to the matter in their report, and (ii)no “reportable events” within the meaning of Item 304(a)(1)(v)of Regulation S-K.

The Company provided E&Y with a copy of the disclosures it is making in this Current Report on Form8-K and has requested E&Y to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of E&Y’s letter, dated October16, 2017 is filed as Exhibit16.1 to this Current Report on Form8-K.

(b) On October11, 2017, the audit committee of the Board approved the appointment of Moss Adams LLP (“Moss Adams”) as the Company’s new independent registered public accounting firm, effective October11, 2017.

During the Company’s two fiscal years ended December31, 2016, and the subsequent interim period through October11, 2017, neither the Company nor anyone acting on behalf of the Company, has consulted with Moss Adams regarding (i)the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Moss Adams concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, (ii)any matter that was subject of a disagreement within the meaning of Item 304(a)(1)(iv)of Regulation S-K, or (iii)any reportable event within the meaning of Item 304(a)(1)(v)of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.


Avinger Inc Exhibit
EX-16.1 2 a17-24007_1ex16d1.htm EX-16.1 Exhibit 16.1     Ernst & Young LLP Suite 1600 560 Mission Street San Francisco,…
To view the full exhibit click here

About AVINGER,INC. (NASDAQ:AVGR)

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

An ad to help with our costs